Heather Freeman
Family · Greenville, SCNPI 1700347374
Payments from drug & device makers
Across 56 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$659
- AbbVie$297
- Sanofi-aventis U.S. LLC$232
- Novo Nordisk$176
- Boehringer Ingelheim$168
- GSK$125
- plus $484 from 13 others
What the payments were for
- Food & beverage$2,142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $659 |
| AbbVie | 13 | $297 |
| Sanofi-aventis U.S. LLC | 3 | $232 |
| Novo Nordisk | 6 | $176 |
| Boehringer Ingelheim | 5 | $168 |
| GSK | 2 | $125 |
| Alkermes, Inc. | 1 | $116 |
| Biohaven Pharmaceuticals, Inc. | 1 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Bayer | 1 | $14 |
| Merck | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,142 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $57,633 |
| OzempicSemaglutide | 33 | $50,724 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $39,008 |
| JardianceEmpagliflozin | 22 | $24,126 |
| EliquisApixaban | 13 | $14,422 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,042 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,805 |
| Varenicline Tartrate | 11 | $3,238 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,161 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,868 |
| Gabapentin | 76 | $1,489 |
| Rosuvastatin Calcium | 73 | $1,224 |
| Atorvastatin Calcium | 171 | $1,068 |
| Potassium Chloride | 39 | $644 |
| Levothyroxine Sodium | 71 | $642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $29 | $57,63336 claims |
| Novo NordiskOzempic | $176 | $50,72433 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $125 | $43,81340 claims |
| Boehringer IngelheimJardiance | $168 | $24,12622 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $64271 claims |
| AbbVieSynthroid | $297 | $16711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Greenville
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Carrie HendersonGreenville$91K
- Michelle StrongGreenville$55K
- Melissa BrownlowGreenville$20K
- Sarah McNightGreenville$15K
- Melissa MotesGreenville$13K
- Matthew KeatonGreenville$10K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.